Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury
Open Access
- 14 August 2021
- journal article
- review article
- Published by Springer Nature in Spinal Cord
- Vol. 59 (12) , 1221-1239
Abstract
Study design: Systematic review.Objectives: To evaluate the impact of cannabinoids on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic spinal cord injury (SCI), with the aim of determining suitability for clinical trials involving SCI patients.Methods: A systematic search was performed in MEDLINE and Embase databases, following registration with PROPSERO (CRD42019149671). Studies evaluating the impact of cannabinoids (agonists or antagonists) on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic SCI were included. Data extracted from relevant studies, included sample characteristics, injury model, neurobehavioural outcomes assessed and study results. PRISMA guidelines were followed and the SYRCLE checklist was used to assess risk of bias.Results: The search returned 8714 studies, 19 of which met our inclusion criteria. Sample sizes ranged from 23 to 390 animals. WIN 55,212-2 (n = 6) and AM 630 (n = 8) were the most used cannabinoid receptor agonist and antagonist respectively. Acute SCI models included traumatic injury (n = 16), ischaemia/reperfusion injury (n = 2), spinal cord cryoinjury (n = 1) and spinal cord ischaemia (n = 1). Assessment tools used assessed locomotor function, pain and anxiety. Cannabinoid receptor agonists resulted in statistically significant improvement in locomotor function in 9 out of 10 studies and pain outcomes in 6 out of 6 studies.Conclusion: Modulation of the endo-cannabinoid system has demonstrated significant improvement in both pain and locomotor function in pre-clinical SCI models; however, the risk of bias is unclear in all studies. These results may help to contextualise future translational clinical trials investigating whether cannabinoids can improve pain and locomotor function in SCI patients.Keywords
Funding Information
- DH | National Institute for Health Research (CS-2015-15-023)
This publication has 55 references indexed in Scilit:
- A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injuryJournal of Neuroinflammation, 2013
- Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord traumaJournal of Neuroinflammation, 2013
- Early Endogenous Activation of CB1 and CB2 Receptors after Spinal Cord Injury Is a Protective Response Involved in Spontaneous RecoveryPLOS ONE, 2012
- Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stressFree Radical Biology and Medicine, 2011
- Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury painBrain Research, 2011
- The Cannabinoid WIN55212-2 Promotes Neural Repair After Neonatal Hypoxia–IschemiaStroke, 2010
- The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injuryNeurobiology of Disease, 2010
- CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategiesBritish Journal of Pharmacology, 2008
- Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?Spinal Cord, 2006
- Effect of Age at Time of Spinal Cord Injury on Behavioral Outcomes in RatJournal of Neurotrauma, 2004